---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-247660"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2024-10-30T23:59:59+00:00"
generated_at: "2026-05-30T08:18:15.925103+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Wave Life Sciences reveals WVE-007 obesity trial startup in Q1 2025, new RNA editing programs

## Summary
- WVE-007 (INHBE GalNAc-siRNA) on track for Phase 1 in Q1 2025; preclinical data show monotherapy, add-on to GLP-1s, and maintenance potential.
- Three new wholly owned GalNAc-RNA editing programs: PNPLA3, LDLR, APOB targeting cardiometabolic diseases; candidate selection expected in 2025.
- Wave aims to have five GalNAc-siRNA or RNA editing programs in the clinic by 2026.
- Proprietary chemistry innovations (PN backbone, N3U) enhance intracellular delivery and RNA editing efficiency.

## SEC filing metadata
- accession: 0001193125-24-247660
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2024-10-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312524247660/0001193125-24-247660-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312524247660/d862759d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-247660
- JSON: https://secwatch.observer/filing/0001193125-24-247660.json
- Plain text: https://secwatch.observer/filing/0001193125-24-247660.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.